Search Results
-
Post
NovoCure Limited Announces Closing of Initial Public Offering
...working capital and general corporate purposes, including clinical trials and research and development and continued commercialization of Optune and its future delivery systems. J.P. Morgan Securities LLC, Deutsche Bank Securities...
-
Post
NovoCure Limited Announces Launch of Initial Public Offering
...corporate purposes, including clinical trials and research and development and continued commercialization of Optune and its future delivery systems. NovoCure Limited will not receive any proceeds from the sale of...
-
Post
NovoCure Limited Announces Launch of Initial Public Offering
...corporate purposes, including clinical trials and research and development and continued commercialization of Optune and its future delivery systems. NovoCure Limited will not receive any proceeds from the sale of...
-
Post
Novocure Reports Second Quarter 2023 Financial Results
...execution and expansion at Novocure,” said Asaf Danziger, Novocure’s Chief Executive Officer. “Our restructured commercial organization has begun driving greater penetration in key markets, the launch of Optune® in France...
-
Post
Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
...Retrospective Review of the Factors Limiting Optune Initiation in GBM patients. Presenter: Luis Carranza Pena. 10:45 a.m. – 12 p.m. PT on Monday, Oct. 2. Tumor Treating Fields (TTFields) in...
-
Post
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
...Pharmaceuticals and Medical Devices Agency (PMDA). In December 2023, Novocure submitted a PMA supplement to the U.S. FDA for Optune Gio® next generation arrays for newly diagnosed glioblastoma. In January,...
-
Post
Novocure Reports First Quarter 2024 Financial Results
...achievements: In April, we met with the FDA in a Day-100 meeting for the PMA application for Optune Lua in non-small cell lung cancer (NSCLC). The meeting was productive with...
-